RCC represents approximately 2-3% of all adult malignancies, and is the seventh most common cancer in men and the ninth most common cancer in women. The European Society of Medical Oncology (ESMO) estimates approximately 209,000 new cases and 102,000 deaths due to renal cell carcinoma per annum worldwide. In the United States, according to the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database, approximately 65,000 new cases and more than 13,500 deaths from kidney and renal pelvic cancers are expected in 2013.About Debio 0932 Debio 0932 is a synthetic small molecule that belongs to the HSP90 family inhibitors. It competes with ATP in binding to the N-terminal portion of HSP90 and inactivates the ATPase activity of the chaperone. Inhibition of HSP90 results in an increased degradation of oncogenic proteins resulting in tumor growth inhibition. In several pre-clinical tumor models, Debio 0932 exhibited potent antitumor activity against a broad range of cancers. In renal cell carcinoma (RCC) in vitro tumor models, Debio 0932 combined with sorafenib, sunitinib or everolimus showed significant additive to synergistic activity in different cell lines. These findings were confirmed in vivo. In a patient-derived in vivo RCC xenograft model, Debio 0932 combined with everolimus demonstrated additive to synergistic antitumor activity. About Debiopharm Group™ Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and access to the largest number of patients worldwide. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.